Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ARVN Stock Alerts

Arvinas (ARVN) News Today

Arvinas logo
$8.93 +0.09 (+0.96%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ARVN Latest News

Insider Selling: Arvinas (NASDAQ:ARVN) CEO Sells $19,969.36 in Stock
May 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30800132
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 2,209 Shares
May 23, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-05-23/
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)
May 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/2099466/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-arvinas-holding-company-arvn/
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296793/0/en/arvinas-employees-give-back-during-company-wide-impact-day.html
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
May 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/bullish-analysts-just-made-noticeable-134017950.html
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN)
May 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-comments-on-arvinas-q2-earnings-nasdaqarvn-2026-05-15/
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/earnings-beat-arvinas-inc-nasdaq-124820731.html
Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock
May 14, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-05-14/
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN
May 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-sells-1331629-shares-of-arvinas-inc-arvn-2026-05-14/
Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock
May 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-arvinas-nasdaqarvn-cao-sells-1919-shares-of-stock-2026-05-13/
Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock
May 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/randy-teel-sells-9657-shares-of-arvinas-nasdaqarvn-stock-2026-05-13/
Insider Selling: Arvinas (NASDAQ:ARVN) Insider Sells 11,108 Shares of Stock
May 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-arvinas-nasdaqarvn-insider-sells-11108-shares-of-stock-2026-05-13/
Insider Selling: Arvinas (NASDAQ:ARVN) CFO Sells 11,139 Shares of Stock
May 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-arvinas-nasdaqarvn-cfo-sells-11139-shares-of-stock-2026-05-13/
Arvinas Q1 2026 earnings preview
May 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/arvinas-q1-2026-earnings-preview/ar-AA22V5La
What To Expect From Arvinas Inc (ARVN) Q1 2026 Earnings
May 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/expect-arvinas-inc-arvn-q1-132006845.html
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903335-arvinas-inc-arvn-q1-2026-earnings-call-transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
May 12, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/05/52502027/rigel-pharmaceuticals-inks-breast-cancer-drug-deal-with-arvinas-pfizer
Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903200-arvinas-fda-approval-validates-the-platform-but-does-not-signal-near-term-profitability
Arvinas Q1 Earnings Call Highlights
May 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/arvinas-q1-earnings-call-highlights-2026-05-12/
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
May 12, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/rigel-strikes-licensing-deal-pfizer-arvinas-breast-cancer-drug-2026-05-12/
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292695/0/en/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292683/0/en/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant.html
Brummer Multi Strategy AB Makes New $1.97 Million Investment in Arvinas, Inc. $ARVN
May 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-brummer-multi-strategy-ab-makes-new-197-million-investment-in-arvinas-inc-arvn-2026-05-11/
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Brokerages
May 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/arvinas-inc-nasdaqarvn-receives-consensus-rating-of-hold-from-brokerages-2026-05-11/
Guggenheim Remains a Buy on Arvinas Holding Company (ARVN)
May 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/1706785/guggenheim-remains-a-buy-on-arvinas-holding-company-arvn/
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Axsome Therapeutics (AXSM)
May 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/1713599/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-and-axsome-therapeutics-axsm/
HC Wainwright Brokers Reduce Earnings Estimates for Arvinas
May 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-brokers-reduce-earnings-estimates-for-arvinas-2026-05-06/
Arvinas Holding Company (ARVN) Gets a Buy from Barclays
May 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1703806/arvinas-holding-company-arvn-gets-a-buy-from-barclays/
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287471/0/en/arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026.html
Arvinas (NASDAQ:ARVN) Shares Gap Down - Should You Sell?
May 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/arvinas-nasdaqarvn-shares-gap-down-should-you-sell-2026-05-04/
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN
May 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hussman-strategic-advisors-inc-buys-new-shares-in-arvinas-inc-arvn-2026-05-04/
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones
May 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/arvinas-arvn-story-shifting-vepdeg-071014124.html
ARVN stock jumps 10% after FDA approves breast cancer drug a month ahead of schedule
May 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/arvn-stock-jumps-10-after-fda-approves-breast-cancer-drug-a-month-ahead-of-schedule/ar-AA22bYTr
Arvinas (NASDAQ:ARVN) Shares Up 9.9% - What's Next?
May 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/arvinas-nasdaqarvn-shares-up-99-whats-next-2026-05-01/
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286140/0/en/arvinas-announces-fda-approval-of-veppanu-vepdegestrant-for-the-treatment-of-esr1m-er-her2-advanced-breast-cancer.html
US FDA approves Pfizer, Arvinas' breast cancer drug
May 1, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01/
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research
April 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/arvinas-nasdaqarvn-downgraded-to-strong-sell-rating-by-zacks-research-2026-04-29/
Arvinas (ARVN) price target increased by 13.60% to 15.54
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/arvinas-arvn-price-target-increased-by-13-60-to-15-54/ar-AA1Zx9vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN)
March 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HITI/pressreleases/861773/analysts-opinions-are-mixed-on-these-healthcare-stocks-gossamer-bio-goss-high-tide-hiti-and-arvinas-holding-company-arvn/
Arvinas (NASDAQ:ARVN) Insider Sells $71,428.50 in Stock
March 20, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-03-20/
Arvinas Reports Positive Phase 1 Data for ARV-102
March 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arvinas-reports-positive-phase-1-data-for-arv-102?utm_source=marketbeat.com&utm_medium=referral
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradation-in-the-csf-of-patients-with-parkinson-s-disease-treated-for-28-days-1035940861
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258013/0/en/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradation-in-the-csf-of-patients-with-parkinson-s-disease-treated-for-28-days.html
Arvinas shows market leadership with jump to 92 RS rating
March 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/arvinas-shows-market-leadership-with-jump-to-92-rs-rating/ar-AA1YoZwW
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and ...
March 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimer-s-and-parkinson-s-diseases-and-related-neurological-disorders-1035918353
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
March 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/11/3253623/0/en/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimer-s-and-parkinson-s-diseases-and-related-neurolo.html
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
March 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4880745-arvinas-inc-arvn-presents-at-barclays-28th-annual-global-healthcare-conference-transcript
Insider Buying: Arvinas (NASDAQ:ARVN) Director Purchases 20,000 Shares of Stock
March 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-03-10/
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts
March 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/arvinas-arvn-narrative-evolving-leadership-100928051.html
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
March 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/arvinas-inc-arvn-makes-significant-progress-on-oncology-and-neurology-trials-1706750/
Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARVN Media Mentions By Week

ARVN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARVN
News Sentiment
▼
0.80

0.82
▲
Average
Medical
News Sentiment

ARVN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARVN Articles
This Week
▼
6

6
▲
ARVN Articles
Average Week

Get the Latest News and Ratings for ARVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:ARVN) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel